By Connor Hart
Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer.
The stock jumped 68%, to $2.61, in after-hours trading Wednesday. Shares ended the regular session 12% lower, at $1.56, putting them down more than 98% in the last year.
The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer.
Additional preclinical data show that the drug exhibits synergistic activity with 5-fluorouracil and irinotecan--two main components commonly used in pancreatic-cancer treatments--when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer, the company said.
Moving forward, Silexion said it will continue developing SIL-204. It plans to initiate toxicology studies with the drug within the upcoming months, as well as advance it into Phase 2/3 clinical trials in the first half of 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:05 ET (23:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。